Jennifer H MacLachlan1, Nicole Allard, Vanessa Towell, Benjamin C Cowie. 1. Epidemiology Unit, WHO Regional Reference Laboratory for Hepatitis B, Victorian Infectious Diseases Reference Laboratory; University of Melbourne, Victoria National Policy and Education Division, Australasian Society for HIV Medicine, New South Wales Epidemiology Unit, WHO Regional Reference Laboratory for Hepatitis B, Victorian Infectious Diseases Reference Laboratory; University of Melbourne, Victoria.
Abstract
OBJECTIVE: The number of Australians living with chronic hepatitis B (CHB) is thought to be increasing, as are adverse outcomes including cirrhosis and liver cancer, however, robust, up-to-date estimates of this burden are limited. Contemporary estimates of the prevalence of CHB in Australia are essential to guide appropriate public health and clinical responses. METHODS: This study used census-based methodology attributing risk of CHB by country of birth and Aboriginal and Torres Strait Islander status, augmented with priority risk-group based estimates. Deterministic mathematical modelling was used for comparison and for validation of census-derived estimates. RESULTS: An estimated 218,000 Australians (plausible range 192,000-284,000) are living with CHB, a significant increase over previous estimates. The prevalence derived using mathematical modelling was similar, at 204,000. Notable differences were observed by geographic area in both prevalence and the populations predominantly affected. It is estimated that only 56% of people living with CHB in Australia have been diagnosed and notified. CONCLUSIONS: The prevalence of CHB in Australia is increasing, with 1% of the population now estimated to be affected. The majority of the burden is experienced by people born overseas in endemic areas, with more than 95% of new cases of CHB entering the population through migration. IMPLICATIONS: It is imperative that more attention and greater resources are devoted to addressing CHB in Australia; to increase the proportion of Australians affected who have been diagnosed and who are on treatment, in accordance with the First National Hepatitis B Strategy.
OBJECTIVE: The number of Australians living with chronic hepatitis B (CHB) is thought to be increasing, as are adverse outcomes including cirrhosis and liver cancer, however, robust, up-to-date estimates of this burden are limited. Contemporary estimates of the prevalence of CHB in Australia are essential to guide appropriate public health and clinical responses. METHODS: This study used census-based methodology attributing risk of CHB by country of birth and Aboriginal and Torres Strait Islander status, augmented with priority risk-group based estimates. Deterministic mathematical modelling was used for comparison and for validation of census-derived estimates. RESULTS: An estimated 218,000 Australians (plausible range 192,000-284,000) are living with CHB, a significant increase over previous estimates. The prevalence derived using mathematical modelling was similar, at 204,000. Notable differences were observed by geographic area in both prevalence and the populations predominantly affected. It is estimated that only 56% of people living with CHB in Australia have been diagnosed and notified. CONCLUSIONS: The prevalence of CHB in Australia is increasing, with 1% of the population now estimated to be affected. The majority of the burden is experienced by people born overseas in endemic areas, with more than 95% of new cases of CHB entering the population through migration. IMPLICATIONS: It is imperative that more attention and greater resources are devoted to addressing CHB in Australia; to increase the proportion of Australians affected who have been diagnosed and who are on treatment, in accordance with the First National Hepatitis B Strategy.
Authors: Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen Journal: Lancet Gastroenterol Hepatol Date: 2019-12-15
Authors: Caroline E van Gemert; Niamh Murphy; Tara A Mitchell; Margaret E Hellard; Lelia Thornton Journal: Ir J Med Sci Date: 2017-12-09 Impact factor: 1.568
Authors: Monica C Robotin; Melanie Q Kansil; Mamta Porwal; Andrew G Penman; Jacob George Journal: Bull World Health Organ Date: 2014-02-04 Impact factor: 9.408
Authors: Simon Graham; Rebecca J Guy; Benjamin Cowie; Handan C Wand; Basil Donovan; Snehal P Akre; James S Ward Journal: BMC Infect Dis Date: 2013-08-31 Impact factor: 3.090
Authors: Patricia C Valery; Elizabeth Powell; Neta Moses; Michael L Volk; Steven M McPhail; Paul J Clark; Jennifer Martin Journal: BMJ Open Date: 2015-04-08 Impact factor: 2.692
Authors: Eric P F Chow; Joseph D Tucker; Frank Y Wong; Eric J Nehl; Yanjie Wang; Xun Zhuang; Lei Zhang Journal: PLoS One Date: 2014-02-24 Impact factor: 3.240